» Articles » PMID: 10961890

Heparin and Heparan Sulfate Bind Interleukin-10 and Modulate Its Activity

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2000 Aug 29
PMID 10961890
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Glycosaminoglycans (GAG) are a group of negatively charged molecules that have been shown to bind and directly regulate the bioactivity of growth factors and cytokines such as basic fibroblast growth factor, transforming growth factor-beta, IL-7, and interferon-gamma. The ability of GAG to interact with human IL-10 (hIL-10) and the effect of these interactions on its biologic activity were analyzed. It was demonstrated by affinity chromatography that hIL-10 binds strongly to heparin-agarose at physiological pH. Biosensor-based binding kinetic analysis indicated an equilibrium dissociation constant, K(d), of 54 nmol/L for this interaction. Human IL-10 stimulated CD16 and CD64 expression on the monocyte/macrophage population within peripheral blood mononuclear cells, with optimal concentrations between 1 and 10 ng/mL. Soluble heparin, heparan sulfate, chondroitin sulfate, and dermatan sulfate were shown to inhibit the hIL-10-induced expression of CD16 and CD64 in a concentration-dependent manner. Heparin and heparan sulfate were most effective with IC(50) values of 100 to 500 microg/mL. Considerably higher concentrations of dermatan sulfate and chondroitin 4-sulfate were required with an IC(50) of 2,000 to 5,000 microg/mL, whereas chondroitin 6-sulfate was essentially inactive. The antagonistic effect of heparin on hIL-10 activity was shown to be dependent on N-sulfation, inasmuch as de-N-sulfated heparin had little or no inhibitory effect on the IL-10- induced expression of CD16, whereas the effect of de-O-sulfated heparin was comparable to that of unmodified heparin. Furthermore, the inhibition of cell-bound proteoglycan sulfation reduced the hIL-10-mediated expression of CD16 molecules on monocytes/macrophages. Taken together, these findings support the hypothesis that soluble and cell-surface GAG and, in particular, their sulfate groups are important in binding and modulation of hIL-10 activity. (Blood. 2000;96:1879-1888)

Citing Articles

Endothelial Dysfunction and Cardiovascular Disease: Hyperbaric Oxygen Therapy as an Emerging Therapeutic Modality?.

Batinac T, Baticic L, Krsek A, Knezevic D, Marcucci E, Sotosek V J Cardiovasc Dev Dis. 2024; 11(12).

PMID: 39728298 PMC: 11677558. DOI: 10.3390/jcdd11120408.


Heparan sulfates and heparan sulfate proteoglycans in hematopoiesis.

Piszczatowski R, Bulow H, Steidl U Blood. 2024; 143(25):2571-2587.

PMID: 38639475 PMC: 11830984. DOI: 10.1182/blood.2023022736.


Glycosaminoglycans: Participants in Microvascular Coagulation of Sepsis.

Li N, Hao R, Ren P, Wang J, Dong J, Ye T Thromb Haemost. 2024; 124(7):599-612.

PMID: 38242171 PMC: 11199054. DOI: 10.1055/a-2250-3166.


VSIG4 interaction with heparan sulfates inhibits VSIG4-complement binding.

Ebstein S, Rafique A, Zhou Y, Krasco A, Montalvo-Ortiz W, Yu L Glycobiology. 2023; 33(7):591-604.

PMID: 37341346 PMC: 10426322. DOI: 10.1093/glycob/cwad050.


Heparan Sulfate Facilitates Binding of hIFN to Its Cell-Surface Receptor hIFNGR1.

Miladinova E, Lilkova E, Krachmarova E, Malinova K, Petkov P, Ilieva N Int J Mol Sci. 2022; 23(16).

PMID: 36012678 PMC: 9408938. DOI: 10.3390/ijms23169415.